FY2025 · period end Dec '25 · from the 10-K filed Feb 27, 2026
Data as filed with the SEC, provided for information only — not investment advice.
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Gross Profit | $3.67B | $3.24B | $3.05B | $3.43B | $4.21B |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B |
| Net Income | $0.99B | $0.87B | $0.85B | $0.95B | $2.00B |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B |
| Total Liabilities | — | — | — | — | — |
| Stockholders' Equity | $7.21B | $6.81B | $6.34B | $5.93B | $6.48B |
| Cash & Equivalents | $0.42B | $0.55B | $0.69B | $0.32B | $0.87B |
| Total Debt | $5.17B | $5.62B | $4.41B | $3.98B | $4.01B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B |
| Capital Expenditures | $0.53B | $0.42B | $0.41B | $0.40B | $0.40B |
| Free Cash Flow | $1.36B | $0.91B | $0.86B | $1.31B | $1.83B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 33.2% | 32.9% | 33.0% | 34.7% | 39.0% |
| Operating Margin | 0.1% | 0.1% | 0.1% | 0.1% | 22.1% |
| Net Margin | 0.1% | 0.1% | 0.1% | 0.1% | 18.5% |
| Return on Equity | 14.2% | 13.2% | 13.9% | 15.2% | 30.8% |
| Return on Assets | 6.1% | 5.8% | 6.4% | 7.2% | 14.7% |
| Debt / Equity | 0.72× | 0.82× | 0.70× | 0.67× | 0.62× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or full history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0001022079-26-000070 | Jun 30, 2026 | Jul 23, 2026 | Jul 24, 2026 00:16 UTC | EDGAR |
| 10-Q | 0001022079-26-000043 | Mar 31, 2026 | Apr 22, 2026 | Apr 23, 2026 00:12 UTC | EDGAR |
| 10-K | 0001022079-26-000015 | Dec 31, 2025 | Feb 26, 2026 | Feb 27, 2026 02:38 UTC | EDGAR |
| 10-Q | 0001022079-25-000218 | Sep 30, 2025 | Oct 21, 2025 | Oct 21, 2025 14:31 UTC | EDGAR |
| 10-Q | 0001022079-25-000175 | Jun 30, 2025 | Jul 23, 2025 | Jul 24, 2025 00:25 UTC | EDGAR |
| 10-Q | 0001022079-25-000120 | Mar 31, 2025 | Apr 23, 2025 | Apr 24, 2025 00:21 UTC | EDGAR |
| 10-K | 0001022079-25-000044 | Dec 31, 2024 | Feb 20, 2025 | Feb 21, 2025 02:30 UTC | EDGAR |
| 10-Q | 0001022079-24-000190 | Sep 30, 2024 | Oct 23, 2024 | Oct 24, 2024 01:24 UTC | EDGAR |
| 10-Q | 0001022079-24-000156 | Jun 30, 2024 | Jul 24, 2024 | Jul 25, 2024 00:44 UTC | EDGAR |
| 10-Q | 0001022079-24-000099 | Mar 31, 2024 | Apr 24, 2024 | Apr 25, 2024 00:12 UTC | EDGAR |
| 10-K | 0001022079-24-000041 | Dec 31, 2023 | Feb 22, 2024 | Feb 23, 2024 02:18 UTC | EDGAR |
| 10-Q | 0001022079-23-000157 | Sep 30, 2023 | Oct 25, 2023 | Oct 26, 2023 00:25 UTC | EDGAR |
Direct links to SEC EDGAR. DGX has additional filings available on the SEC site.
6 numbers QUEST DIAGNOSTICS INC later changed — same XBRL tag, both filings linked.
Gross Profit·3 months to Mar 2017
Major restatementwas$734M
Revised down in a 10-K.
Gross Profit·3 months to Jun 2017
Major restatementwas$773M
Revised down in a 10-K.
Gross Profit·3 months to Sep 2017
Major restatementwas$741M
Revised down in a 10-K.
Gross Profit·3 months to Dec 2017
Notable restatementwas$742M
Revised down in a 10-K.
Net Cash Provided by (Used in) Operating Activities·Q1 2016
Notable restatementwas$143M
Revised up in a 10-Q. Any P/OCF built on the original was 6.5% too high.
Net Cash Provided by (Used in) Operating Activities·FY 2016
Notable restatementwas$1.1B
Revised up in a 10-K. Any P/OCF built on the original was 4.2% too high.
DGX is not the only one.
See every restatement we've found across the market — or get an alert the next time DGX revises a number.
Restatements are detected by comparing every vintage of a fact across all of QUEST DIAGNOSTICS INC's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows DGX's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling QUEST DIAGNOSTICS INC — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on DGX yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on DGX and publish the result to your public profile.
Ask about QUEST DIAGNOSTICS INC
Continue in Workspace — cited answers on DGX, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate, with delisted companies kept in.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs